for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Stealth BioTherapeutics Corp

MITO.OQ

Latest Trade

1.84USD

Change

0.00(0.00%)

Volume

2,834

Today's Range

1.84

 - 

1.85

52 Week Range

0.91

 - 

14.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.84
Open
1.85
Volume
2,834
3M AVG Volume
2.70
Today's High
1.85
Today's Low
1.84
52 Week High
14.40
52 Week Low
0.91
Shares Out (MIL)
413.30
Market Cap (MIL)
899.11
Forward P/E
-16.03
Dividend (Yield %)
--

Latest Developments

More

Stealth Biotherapeutics Files For Resale Of Upto 9.8 Mln ADSS Of Co By Selling Shareholder

Stealth Biotherapeutics Q1 Loss Per Share $0.04

Stealth Biotherapeutics Files For Mixed Shelf Of Up To $75.0 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Stealth BioTherapeutics Corp

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. The Company is primarily focused on developing mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, neurodegenerative and metabolic diseases. The Company is engaged in developing its product pipelines, which include Elamipretide, SBT-20 and SBT-272.

Industry

Biotechnology & Drugs

Contact Info

190 Elgin Avenue, George Town

GEORGE TOWN, MA

KY1-9005

Cayman Islands

+1.617.6006888

https://www.stealthbt.com/

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.410

2019

-0.190

2020(E)

-0.113
Price To Earnings (TTM)
--
Price To Sales (TTM)
42.64
Price To Book (MRQ)
25.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
602.97
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-180.68
Return on Equity (TTM)
-83.98

Latest News

Latest News

BRIEF-Stealth Biotherapeutics Files For Resale Of Upto 9.8 Mln ADSS Of Co By Selling Shareholder

* STEALTH BIOTHERAPEUTICS FILES FOR RESALE OF UPTO 9.8 MILLION ADSS OF CO BY SELLING SHAREHOLDER - SEC FILING Source: https://bit.ly/2YYSlqf Further company coverage:

U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on Monday. HIGHLIGHTS * Acushnet Holdings Corp : Stephens raises target price to $27 from $24 * Equity Residential...

BRIEF-Stealth Biotherapeutics Q1 Loss Per Share $0.04

* STEALTH BIOTHERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Stealth Biotherapeutics Files For Mixed Shelf Of Up To $75.0 Mln

* STEALTH BIOTHERAPEUTICS CORP FILES FOR MIXED SHELF OF UP TO $75.0 MILLION - SEC FILING Source text: [https://bit.ly/2JK8Mjb] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Stealth Biotherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights

* STEALTH BIOTHERAPEUTICS REPORTS FISCAL YEAR 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

Stealth Bio's neuromuscular disorder drug fails trial; shares plummet

Stealth BioTherapeutics Corp's shares crashed on Friday after its lead neuromuscular disorder drug candidate failed to help patients walk better and reduce fatigue, a major setback to the company's wide mitochondrial diseases pipeline.

Stealth BioTherapeutics' neuromuscular disorder drug fails late-stage study

Stealth BioTherapeutics Corp said on Friday its drug to treat neuromuscular diseases failed to meet the main goals of a late-stage trial.

UPDATE 1-IFR Americas ECM Pipeline

8x8 (US, telecom equipment) - $250m 5y CB priced at 0.5%, up 30% versus talk of 0.5%-1% and 27.5%-32.5%. MS. Upsized from $200m.

IFR Americas ECM Pipeline

8x8 (US, telecom equipment) - $250m 5y CB priced at 0.5%, up 30% versus talk of 0.5%-1% and 27.5%-32.5%. MS. Upsized from $200m.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up